Compare Canopy Growth Corp (CGC) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Canopy Growth Corp vs Synopsys, Inc. — how do they compare? Canopy Growth Corp trades at $0.97 (market cap $398.46M), while Synopsys, Inc. trades at $425.07 (market cap $81.55B). The key difference: Synopsys, Inc. is far larger — about 204.7× Canopy Growth Corp's market cap. Which is the better fit depends on your goals.
| CGC | SNPS | |
|---|---|---|
Market Cap | $398.46M | $81.55B |
Sector | Health | Technology |
52-Week High | $1.92 | $645.59 |
52-Week Low | $0.86 | $380.47 |
Enterprise Value | $337.90M | $89.91B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
Synopsys (SNPS) trades at $433.82, down 2.6% today, with a bearish technical signal from moving averages but oversold short-term RSI at 29.08. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $3.35 surpassing the $3.15 estimate. Revenue grew to $7.05B in 2025, though net income margin compressed to 8.91%. Valuation multiples remain elevated with a P/E of 99.27 and P/S of 9.16. Recent news highlights Synopsys' strategic pivot toward AI-driven design tools and multiphysics solutions.
Outlook: Analyst consensus is bullish with an average price target of $558.33, implying 29% upside, supported by 24 buy ratings. Risks include integration challenges from the Ansys acquisition, competitive pressures in EDA software, and volatility in semiconductor capex. The stock's high valuation requires sustained execution on AI-related growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
